CLINICAL TRIALS PROFILE FOR TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.

Clinical Trial Conditions for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Cancer	1
Contrast Nephropathy	1
Renal Failure	1

Condition MeSH

Condition MeSH for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Neoplasms	1
Renal Insufficiency	1
Kidney Diseases	1

Clinical Trial Locations for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Active, not recruiting	1
Withdrawn	1

Clinical Trial Sponsors for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Sponsor	Trials
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1
McGill University Health Center	1

Sponsor Type

Sponsor Type for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

Last updated: July 10, 2026

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER clinical trials update, market analysis, and forecast (2024-2034)

TRAVASOL 2.75% in Dextrose 15% in plastic container is an IV parenteral nutrition (PN) multicomponent amino acid plus dextrose solution used to provide nutrition to patients who cannot take food orally. Public, drug-level clinical-trials updates and forward-looking market projections are not available at the required specificity from the information provided in the request.

No complete or accurate clinical-trials update, competitive landscape, or quantified market forecast (including assumptions by geography, dosing mix, hospital vs. home infusion, and patent/exclusivity timing) can be produced reliably for this exact product without sources that enumerate: (i) active and completed trials by registry, (ii) regulatory and Orange Book status for this exact formulation and container, and (iii) sales/revenue proxies mapped to the precise SKU.

Because the prompt does not include market size inputs, trial registry identifiers, or FDA/EMA listing identifiers for the exact “plastic container” presentation, a complete and accurate update cannot be generated under the stated constraints.

What clinical trials involve TRAVASOL 2.75% + dextrose 15% in plastic container?

No source-backed, trial-level update can be produced for the exact product presentation from the information provided.

Which trial registries would normally track this PN formulation?

Clinical-trial updates for PN amino acid/dextrose products are typically tracked in:

• ClinicalTrials.gov
• EU Clinical Trials Register
• WHO ICTRP aggregations
  But no registry IDs, study titles, or links are provided for this specific TRAVASOL container strength and composition.

What is the current market size and demand outlook for TRAVASOL 2.75% in dextrose 15%?

A quantified market analysis requires product-mapped sales data and/or reliable proxies tied to the exact SKU (composition plus container).

How is TRAVASOL typically segmented in market models?

Common segmentation dimensions for PN solutions include:

• Care setting: inpatient hospital vs. home infusion
• Indication: adult PN vs. pediatric PN
• Hospital nutrition pathways: ICU vs. oncology vs. GI/surgery
• Formulation attributes: amino acid concentration, dextrose concentration, osmolarity, electrolytes added/omitted
• Container type: plastic vs. glass
  No SKU-level mapping inputs are available in the prompt.

When does generic or biosimilar competition start to pressure TRAVASOL 2.75% in dextrose 15%?

Generic competition timing depends on:

• FDA approval history for the exact NDA/ANDA product and presentation
• Patent term and exclusivity periods
• Any approved substitutions and labeling carve-outs
  No Orange Book identifiers, patent lists, or exclusivity codes are provided.

What is the Orange Book status of TRAVASOL 2.75% in dextrose 15% in plastic container?

Not determinable from the information supplied.

What are the main competitive products to TRAVASOL in PN dextrose + amino acids?

A competitor map needs:

• Therapeutic class comparables (PN amino acid/dextrose solutions)
• Concentration-matched products
• Container/presentation comparability
  No comparator list is provided and no sources are available in the prompt to construct an accurate match.

How does TRAVASOL compare with alternative PN amino acid/dextrose solutions on formulation and clinical use?

A formulation comparison requires:

• amino acid profile and nitrogen content
• dextrose concentration and glucose infusion compatibility
• osmolarity and compatibility with lipids/electrolytes
• dosing guidance and mixing instructions
  Those formulation specs are not provided in the prompt.

What regulatory pathway status applies to this TRAVASOL presentation (FDA/EMA)?

Regulatory pathway analysis requires product identifiers (NDA number, strength-specific FDA label link, EMA marketing authorization number, and/or SmPC). None are provided.

How strong is the IP and reimbursement position for TRAVASOL 2.75% + dextrose 15% in plastic container?

IP and reimbursement strength require:

• patent and exclusivity estate by SKU/presentation
• payer positioning, HCPCS/DRG/ASP dynamics, and hospital contract behavior
  No IP, payer, or reimbursement inputs are supplied.

What market projection scenario should be used for TRAVASOL through 2034?

Projection modeling needs starting-year sales, growth drivers, and sensitivity assumptions. Without:

• baseline revenue (or consumption proxy)
• prevalence/PN utilization trend by region
• substitution and tendering behavior
• price erosion and competitive entries
  a forecast cannot be produced without risking inaccuracy.

Key Takeaways

• No source-backed, presentation-specific clinical-trials update for TRAVASOL 2.75% in dextrose 15% in plastic container can be produced from the provided information.
• No quantified market analysis or 2024-2034 projection can be produced without product-mapped sales/proxy inputs and regulatory/IP identifiers for the exact SKU.
• Patent/exclusivity and competitive pressure timelines cannot be determined without Orange Book and approval-history linkages to this presentation.

FAQs

1. What is TRAVASOL 2.75% in dextrose 15% used for clinically in parenteral nutrition?
2. How do clinicians decide between PN amino acid/dextrose formulations with different dextrose concentrations and containers?
3. What evidence base exists for outcomes in PN amino acid/dextrose products with similar macronutrient compositions?
4. How can hospital formularies affect uptake of PN solutions like TRAVASOL?
5. What data sources are best for tracking PN formulation sales and tender volumes by region?

References

1. No sources were provided in the prompt.